Markets

Cancer immunotherapy biotech Arcus Biosciences files for $100 million IPO

Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The Hayward, CA-based company was founded in 2015 and booked $1 million in sales for the 12 months ended December 31, 2017. It plans to list on the NYSE under the symbol RCUS. Citi, Goldman Sachs and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer immunotherapy biotech Arcus Biosciences files for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos